Phase I trial of alpha-particle therapy with actinium-225 (Ac-225)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML Meeting Abstract


Authors: Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Douer, D.; Levy, M. Y.; Estey, E.; Kantarjian, H. M.; Earle, D.; Cicic, D.; Scheinberg, D. A.
Abstract Title: Phase I trial of alpha-particle therapy with actinium-225 (Ac-225)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036901586
PROVIDER: wos
Notes: Meeting Abstract: 7050 -- Source: Wos
MSK Authors
  1. Jae Hong Park
    127 Park
  2. Dan Douer
    79 Douer
Related MSK Work